TrialPath

Find a study

Studies of GLP-1, incretin, and related peptide medications for weight and metabolic health.

Match me to a study

39 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

36 studies on the map

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes — Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC, GilbertExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) — Altasciences Clinical LA, Inc., CypressResistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity — St. Jude Children's Research Hospital, MemphisSemaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants — Celerion Clinical Research, TempeTirzepatide for Alcohol Use Disorder — Keck School of Medicine, University of Southern California, Los AngelesSemaglutide for Post-Smoking Cessation Weight Management — The University of Texas at Austin, AustinNon-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES) — National Institutes of Health Clinical Center, BethesdaA Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function — Floridian Clinical Research, LLC, Miami LakesProof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss — DM Clinical Research - Phoenix, PhoenixA Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight — Arizona Clinical Trials, ChandlerA Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults — Frontage Clinical Services, Inc., SecaucusTIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation — Cleveland Clinic, ClevelandTargeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis — Johns Hopkins University, BaltimoreA Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet — Advent Health-Res Inst, OrlandoPhase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy — Central Research Associates, LLC dba Flourish Research, BirminghamEffect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity — Fortrea Clinical Research Unit - Daytona Beach, Daytona BeachEfficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder — Johns Hopkins University, BaltimoreThe Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes — Mayo Clinic in Rochester, RochesterBZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants — Ohio State University Comprehensive Cancer Center, ColumbusPhysiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents — Childrens Hospital Colorado, AuroraFeasibility of Semaglutide in Advanced Lung Disease — University of Pennsylvania Perelman School of Medicine, PhiladelphiaStudy to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency — Syneos Miami, MiamiA Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight — The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, ChandlerEvaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events — Diablo Clinical Research, Inc., Walnut CreekObesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment — Yale Pediatric Diabetes Center, Adult and Children's Progam, New HavenInterleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease — Houston Methodist Research Institute, HoustonMechanisms of Semaglutide Therapy in Heart Failure Patients — Greenstone Biosciences, Palo AltoGlucagon-Like Peptide-1 Receptor Agonist in ADPKD — University of Colorado - Anschutz Medical Campus, AuroraIncretin Microdosing for Cardiometabolic Health in People With HIV — The University of Texas Health Science Center at Houston, HoustonTirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity — Clinical and Translational Research Unit, Palo AltoEffect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity — Massachusetts General Hospital, BostonPharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation — Mclean Hospital, BelmontRandomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant — Virginia Commonwealth University, RichmondEffects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults — University of Texas Health Science Center at San Antonio, San AntonioA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide — Helios Clinical Research - Phoenix, PhoenixBone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy — University of Virginia Medical Center, Charlottesville